These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32398059)

  • 21. Take -home naloxone rescue kits following heroin overdose in the emergency department to prevent opioid overdose related repeat emergency department visits, hospitalization and death- a pilot study.
    Papp J; Vallabhaneni M; Morales A; Schrock JW
    BMC Health Serv Res; 2019 Dec; 19(1):957. PubMed ID: 31829228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The extent of and factors associated with self-reported overdose and self-reported receipt of naloxone among people who inject drugs (PWID) in England, Wales and Northern Ireland.
    O'Halloran C; Cullen K; Njoroge J; Jessop L; Smith J; Hope V; Ncube F
    Int J Drug Policy; 2017 Aug; 46():34-40. PubMed ID: 28586701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Racial differences in overdose training, naloxone possession, and naloxone administration among clients and nonclients of a syringe services program.
    Jones AA; Park JN; Allen ST; Schneider KE; Weir BW; Hunt D; Sherman SG
    J Subst Abuse Treat; 2021 Oct; 129():108412. PubMed ID: 34080560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expanding the accessibility of harm reduction services in the United States: Measuring the impact of an automated harm reduction dispensing machine.
    Arendt D
    J Am Pharm Assoc (2003); 2023; 63(1):309-316. PubMed ID: 36549931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19 vaccine implementation at a syringe services program: experiences of frontline staff.
    Plesons M; Soto Sugar SE; Chimbaru R; McDonald G; Friedman L; Thompson E; Bazzi AR; Tookes HE; Bartholomew TS
    BMC Health Serv Res; 2024 Oct; 24(1):1260. PubMed ID: 39427164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polysubstance use in rural West Virginia: Associations between latent classes of drug use, overdose, and take-home naloxone.
    Schneider KE; O'Rourke A; White RH; Park JN; Musci RJ; Kilkenny ME; Sherman SG; Allen ST
    Int J Drug Policy; 2020 Feb; 76():102642. PubMed ID: 31918401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Designing, implementing and evaluating the overdose response with take-home naloxone model of care: An evaluation of client outcomes and perspectives.
    Lintzeris N; Monds LA; Bravo M; Read P; Harrod ME; Gilliver R; Wood W; Nielsen S; Dietze PM; Lenton S; Shanahan M; Jauncey M; Jefferies M; Hazelwood S; Dunlop AJ; Greenaway M; Haber P; Ezard N; Malcom A
    Drug Alcohol Rev; 2020 Jan; 39(1):55-65. PubMed ID: 31774221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implementation of Syringe Services Programs to Prevent Rapid Human Immunodeficiency Virus Transmission in Rural Counties in the United States: A Modeling Study.
    Goedel WC; King MRF; Lurie MN; Galea S; Townsend JP; Galvani AP; Friedman SR; Marshall BDL
    Clin Infect Dis; 2020 Mar; 70(6):1096-1102. PubMed ID: 31143944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimating the number of people who inject drugs and syringe coverage in Australia, 2005-2016.
    Kwon JA; Iversen J; Law M; Dolan K; Wand H; Maher L
    Drug Alcohol Depend; 2019 Apr; 197():108-114. PubMed ID: 30802734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The University of Miami Infectious Disease Elimination Act Syringe Services Program: A Blueprint for Student Advocacy, Education, and Innovation.
    Tookes H; Bartholomew TS; St Onge JE; Ford H
    Acad Med; 2021 Feb; 96(2):213-217. PubMed ID: 32590466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Syringe Decriminalization Advocacy in Red States: Lessons from the North Carolina Harm Reduction Coalition.
    Cloud DH; Castillo T; Brinkley-Rubinstein L; Dubey M; Childs R
    Curr HIV/AIDS Rep; 2018 Jun; 15(3):276-282. PubMed ID: 29740734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Baseline differences in characteristics and risk behaviors among people who inject drugs by syringe exchange program modality: an analysis of the Miami IDEA syringe exchange.
    Iyengar S; Kravietz A; Bartholomew TS; Forrest D; Tookes HE
    Harm Reduct J; 2019 Jan; 16(1):7. PubMed ID: 30674334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Racial disparities in use of syringe service programs in King County, WA: a comparison of two cross-sectional surveys.
    Salow K; Jack HE; Tinsley J; Banta-Green CJ; Kingston S; Iles-Shih M; Tsui JI; Glick S
    Harm Reduct J; 2023 Sep; 20(1):133. PubMed ID: 37704989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Injection and Sexual Behavior Profiles among People Who Inject Drugs in Miami, Florida.
    Chueng TA; Tookes HE; McLaughlin M; Arcaro-Vinas AM; Serota DP; Bartholomew TS
    Subst Use Misuse; 2022; 57(9):1374-1382. PubMed ID: 35686722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduction of Injection-Related Risk Behaviors After Emergency Implementation of a Syringe Services Program During an HIV Outbreak.
    Patel MR; Foote C; Duwve J; Chapman E; Combs B; Fry A; Hall P; Roseberry J; Brooks JT; Broz D
    J Acquir Immune Defic Syndr; 2018 Apr; 77(4):373-382. PubMed ID: 29271829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acceptability of safe drug consumption spaces among people who inject drugs in rural West Virginia.
    O'Rourke A; White RH; Park JN; Rodriguez K; Kilkenny ME; Sherman SG; Allen ST
    Harm Reduct J; 2019 Aug; 16(1):51. PubMed ID: 31470864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Community Perceptions of Comprehensive Harm Reduction Programs and Stigma Towards People Who Inject Drugs in Rural Virginia.
    Baker LS; Smith W; Gulley T; Tomann MM
    J Community Health; 2020 Apr; 45(2):239-244. PubMed ID: 31502098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acceptability and anticipated effectiveness of a safe supply of opioids, among people who inject opioids in King County, WA.
    Palayew A; Banta-Green CJ; Lamont M; Damper D; Moreno C; Goodreau SM; Mooney SJ; Glick SN
    Int J Drug Policy; 2024 May; 127():104389. PubMed ID: 38522176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Syringe access and health harms: Characterizing "landscapes of antagonism" in California's Central Valley.
    Syvertsen JL; Pollini RA
    Int J Drug Policy; 2020 Jan; 75():102594. PubMed ID: 31775079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fentanyl-contaminated drugs and non-fatal overdose among people who inject drugs in Baltimore, MD.
    Park JN; Weir BW; Allen ST; Chaulk P; Sherman SG
    Harm Reduct J; 2018 Jul; 15(1):34. PubMed ID: 29976195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.